---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-243671"
form_type: "8-K"
ticker: "KRRO"
cik: "0001703647"
company_name: "Korro Bio, Inc."
filed_at: "2023-09-27T23:59:59+00:00"
generated_at: "2026-06-10T08:12:06.956880+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Frequency Therapeutics terminates ATM equity agreement, transfers Nasdaq listing to Capital Market

## Summary
- Terminated Equity Distribution Agreement with Oppenheimer; only $50,000 in net proceeds raised from 12,767 shares sold.
- Nasdaq approved transfer from Global Select Market to Capital Market effective Sept 28, 2023.
- Extended bid price compliance period to March 25, 2024; company plans reverse stock split if needed.
- Merger with Korro Bio remains pending; S-4 registration statement already filed.

## SEC filing metadata
- accession: 0001193125-23-243671
- form_type: 8-K
- ticker: KRRO
- cik: 0001703647
- company_name: Korro Bio, Inc.
- filed_at: 2023-09-27T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703647/000119312523243671/0001193125-23-243671-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703647/000119312523243671/d506578d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-243671
- JSON: https://secwatch.observer/filing/0001193125-23-243671.json
- Plain text: https://secwatch.observer/filing/0001193125-23-243671.txt

## Key facts
- Material Agreements
  Korro Bio, Inc. terminated Sales Agreement with Oppenheimer & Co. Inc. (effective 2023-09-26).
  - Action: termination
  - Agreement: atm program
  - Counterparty: Oppenheimer & Co. Inc.
  - Effective: 2023-09-26
  source text: On September 26, 2023, the Company delivered written notice to Oppenheimer of termination of the Sales Agreement pursuant to Section 11(b) thereof, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703647/000119312523243671/0001193125-23-243671-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.